百诚医药 reported revenue of ¥0.30B for the period ended 2026-06-30, -8.4% year on year. Net income was ¥0.00B, a 0.5% net margin on a 47.1% gross margin. The largest revenue line is 研发技术成果转化 at 47% of the total. Free cash flow for the period was ¥-0.02B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.30B | -8.4% |
| Gross profit | ¥0.14B | — |
| Operating income | ¥0.00B | — |
| Net income | ¥0.00B | -48.6% |
| Gross margin | 47.1% | Net margin 0.5% |
| Revenue Q/Q | -10.3% | — |
| Segment | Revenue | Share |
|---|---|---|
| 研发技术成果转化 | ¥0.14B | 47.0% |
| 商业化生产 | ¥0.06B | 19.7% |
| CDMO | ¥0.03B | 11.3% |
| 临床前药学研究 | ¥0.03B | 11.2% |
| 临床服务 | ¥0.03B | 8.2% |
| 其他 | ¥0.00B | 1.6% |
| 权益分成 | ¥0.00B | 1.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.16B | 52.9% |
| R&D | ¥0.07B | 24.6% |
| SG&A | ¥0.07B | 21.6% |
| Tax & other | ¥-0.00B | -0.3% |
| Item | Amount |
|---|---|
| Total assets | ¥3.75B |
| Total liabilities | ¥1.26B |
| Shareholders' equity | ¥2.49B |
| Equity / assets | 66.5% |
| Operating cash flow | ¥0.00B |
| Capital expenditure | ¥0.02B |
| Free cash flow | ¥-0.02B |
| Cash conversion (OCF / net income) | -307% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
天益医疗 ・ 金埔园林 ・ 雅创电子 ・ 风光股份 ・ 明月镜片 ・ 兆讯传媒 ・ 何氏眼科 ・ 鸿铭股份 ・ 骏成科技 ・ 瑜欣电子 ・ 洁雅股份 ・ 军信股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies